MARLBOROUGH, Mass.,
Jan. 26, 2016 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a
biotechnology company focused on discovering and developing
innovative therapies primarily in the areas of dermatology and
ophthalmology today announced that the Company's President and CEO,
Dr. Geert Cauwenbergh, will present
at the 18th Annual BIO CEO & Investor Conference on
Tuesday, February 9, 2016 at
2:30 p.m. ET in New York
City.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Cauwenbergh will present a corporate overview that includes
the Company's clinical programs and the multiple business
development opportunities available based on RXi's proprietary
sd-rxRNA® platform, immunotherapy agents and extensive intellectual
property portfolio. The presentation will be webcast and
available on the "Investors - Event Calendar" section of the
Company's website, www.rxipharma.com.
To schedule a meeting with RXi Pharmaceuticals' management team
at this conference, contact Investor Relations at
ir@rxipharma.com.
About the BIO CEO & Investor Conference
Now in its eighteenth year, the BIO CEO & Investor
Conference is the largest investor conference focused on
established and emerging publicly traded and select private biotech
companies. Each year this conference provides a neutral forum where
institutional investors, industry analysts, and senior
biotechnology executives have the opportunity to shape the future
investment landscape of the biotechnology industry. The
conference will be held February 8-9,
2016 at the Waldorf Astoria in New
York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the areas of dermatology and
ophthalmology that address high-unmet medical needs. Building
on the pioneering work of RXi's Scientific Advisory Board Chairman
and Nobel Laureate Dr. Craig Mello,
our discovery and clinical development programs are based on siRNA
technology as well as immunotherapy agents. These compounds
include, but are not limited to, our proprietary, self-delivering
RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular
scar formation. It also includes an immunomodulator, Samcyprone™, a
proprietary topical formulation of diphenylcyclopropenone (DPCP),
for the treatment of disorders such as warts, alopecia areata,
non-malignant skin tumors and cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for multiple product and business development
opportunities across a broad spectrum of therapeutic areas. We are
committed to being a partner of choice for academia, small
companies, and large multinationals. We welcome ideas and proposals
for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-18th-annual-bio-ceo--investor-conference-300209455.html
SOURCE RXi Pharmaceuticals Corporation